Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Average Recommendation of “Buy” from Analysts

Kailera Therapeutics, Inc. (NASDAQ:KLRA) has been assigned an average rating of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $42.75.

Several equities analysts recently weighed in on KLRA shares. Evercore started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating on the stock. Zacks Research upgraded shares of Kailera Therapeutics to a “hold” rating in a report on Wednesday, May 13th. Leerink Partners started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating and a $36.00 target price on the stock. William Blair started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $48.00 target price on the stock.

Kailera Therapeutics Trading Down 7.7%

NASDAQ:KLRA opened at $19.37 on Friday. Kailera Therapeutics has a twelve month low of $18.85 and a twelve month high of $28.23.

Insiders Place Their Bets

In other Kailera Therapeutics news, Director Andrew T. Kaplan bought 8,398,438 shares of the business’s stock in a transaction on Monday, April 20th. The shares were purchased at an average price of $16.00 per share, with a total value of $134,375,008.00. Following the completion of the acquisition, the director directly owned 26,255,581 shares of the company’s stock, valued at approximately $420,089,296. The trade was a 47.03% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Adam Koppel acquired 1,562,500 shares of the stock in a transaction that occurred on Monday, April 20th. The shares were bought at an average price of $16.00 per share, with a total value of $25,000,000.00. Following the completion of the purchase, the director owned 22,583,268 shares in the company, valued at $361,332,288. The trade was a 7.43% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased a total of 10,460,938 shares of company stock valued at $167,375,008 in the last ninety days.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.